[stock_market_widget type=”card” template=”basic2″ assets=”MBX” realtime=”true” api=”yahoo-finance”]
Chronic hypoparathyroidism is one of those conditions that rarely makes headlines, yet for the estimated 250,000 people living with it across the U.S. and Europe, it is a daily and often exhausting reality. The parathyroid glands, four tiny structures sitting behind the thyroid in your neck, are responsible for releasing parathyroid hormone (PTH), which regulates calcium in the blood. When those glands fail or are removed, most commonly during neck or thyroid surgery, the body loses its ability to maintain normal calcium levels. The result is a cascade of symptoms that can include muscle cramps, tingling, cognitive difficulties, seizures, and in serious cases, dangerous heart rhythm problems. The current standard of care does not replace the missing hormone. Instead, patients manage symptoms with high doses of oral calcium and active vitamin D supplements, an approach that treats the surface problem but not the underlying cause, and that can, over time, damage the kidneys by driving excess calcium into the urine. It is a rare and underserved condition, and it has had very limited treatment options for a long time.
That gap is exactly what MBX Biosciences, Inc. (NASDAQ: MBX) is trying to close with its lead drug candidate, canvuparatide (MBX 2109), a once-weekly injectable parathyroid hormone prodrug. A prodrug is a compound designed to convert into its active form gradually after being administered, which in this case is intended to provide a steady, infusion-like release of PTH over a full week rather than the sharp peaks and valleys that come with daily injections. The company released two important sets of data at once: the full results from its 12-week Phase 2 Avail™ trial, and new one-year data from an ongoing open-label extension study. To put those terms plainly, a Phase 2 trial is a controlled study designed to test whether a drug actually works and is safe in patients, while an open-label extension is a follow-on study where participants who completed the original trial continue taking the drug so researchers can track longer-term effects. Taken together, these two datasets give a more complete picture of how canvuparatide performs not just in the short term, but over a sustained period.
The Phase 2 results were encouraging. At 12 weeks, 63% of patients receiving canvuparatide met the study’s primary goal, which required maintaining normal blood calcium levels while reducing or eliminating their dependence on active vitamin D and high-dose calcium supplements. Only 31% of those on placebo met the same bar, a statistically significant difference. What made the one-year data particularly notable was that the response rate held. At the one-year mark, 57% of evaluable patients were still meeting the responder definition, with no use of rescue therapy in the final week. Kidney function, as measured by eGFR (a standard indicator of how well the kidneys are filtering blood), improved from baseline and stayed improved through the full year. Urinary calcium, the marker that signals the kidneys are being overloaded by conventional therapy, decreased and remained within normal range. Bone metabolism markers aligned with what would be expected from physiologic PTH replacement, meaning the bones were responding in a healthy, normal pattern. Retention in the study was high, with 90% of patients who entered the extension still on treatment at the one-year point, and no treatment-related serious adverse events were reported. Injection site reactions were noted in 10% of patients.
The company also confirmed that its Phase 3 pivotal trial, the large-scale study required before seeking regulatory approval, remains on track to begin in the third quarter of 2026. A successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration was completed in March 2026, a constructive signal that the agency has reviewed the study design and provided feedback that supports moving forward. Canvuparatide already holds orphan drug designation from the FDA, a status granted to therapies targeting rare diseases that can provide regulatory and commercial advantages on the path to approval. From a financial standpoint, the company carries a clean balance sheet with approximately $440 million in cash as of its most recent quarterly report, and holds a $250 million at-the-market shelf registration that has not yet been drawn on, meaning the company has not needed to tap it to fund operations to date.
Beyond hypoparathyroidism, MBX Biosciences is also advancing MBX 4291, an obesity drug candidate currently in Phase 1 development that showed initial data supporting the potential for once-monthly dosing, adding a meaningful second dimension to the company’s pipeline. The Phase 3 launch of canvuparatide later this year represents the most consequential step in the company’s development timeline, and the durability shown in the one-year data materially reduces the uncertainty heading into that trial. If Phase 3 confirms what Phase 2 suggested, canvuparatide could become the first once-weekly peptide therapy for a condition that, for far too long, has had to make do with treatments that address symptoms rather than cause.
